The global ferritin testing market size is expected to be valued at US$ 3.7 million in 2026 and projected to reach US$ 5.6 million by 2033, growing at a CAGR of 6.2% between 2026 and 2033.
This growth is driven primarily by the high and persistent global burden of iron deficiency anemia and the increasing recognition of ferritin as the preferred biomarker for assessing body iron stores. The market further benefits from the rising prevalence of chronic kidney disease-related anemia, expansion of maternal health and antenatal screening programs, and technological advances in high-sensitivity immunoassays and point-of-care platforms that improve diagnostic access and clinical decision-making.